Coagulation factors with improved properties for hemophilia gene therapy

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 2, 2004, Pages 227-237

  Pipe, Steven W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bioengineering; Factor IX; Factor VIII; Gene therapy; Hemophilia; Recombinant

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 4; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANTIBODY ENGINEERING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; REVIEW; THROMBOCYTE ACTIVATION; VIRAL GENE THERAPY;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RNA, MESSENGER;

EID: 2342542505     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-825636     Document Type: Review

References (104)

1. Rogoff EG, Guirguis HS, Lipton RA, et al. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia. Thromb Haemost 2002;88:545-553
2. Mitterer A, Mundt W, Bjornson E, Dorner F. Development of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM). J Thromb Haemost 2003;1:P1652 (abst)
3. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998;79:932-937
4. Saenko EL, Ananyeva NM, Moayeri M, Ramezani A, Hawley RG. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther 2003;3:27-41
5. Saenko EL, Ananyeva NM, Shima M, Hauser CA, Pipe SW. The future of recombinant coagulation factors. J Thromb Haemost 2003;1:922-930
6. Bontempo FA, Lewis JH, Gorenc TJ, et al. Liver transplantation in hemophilia A. Blood 1987;69:1721-1724
7. Kelly DA, Summerfield JA, Tuddenham EG. Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. Br J Haematol 1984;56:535-543
8. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 1985;317:729-730
9. Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985;317:726-729
10. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999;274:19587-19592
11. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987;262:8443-8446
12. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994;269:11601-11605
13. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988;263:5230-5234
14. Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood 1987;70:1679-1682
15. Galbusera M, Zoja C, Donadelli R, et al. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. Blood 1997;90:1558-1564
16. Schick PK, Walker J, Profeta B, Denisova L, Bennett V. Synthesis and secretion of von Willebrand factor and fibronectin in megakaryocytes at different phases of maturation. Arterioscler Thromb Vasc Biol 1997;17:797-801
17. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest 1998;101:613-624
18. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977;60:390-404
19. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992;79:3130-3137
20. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001;344:1735-1742
21. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 1997; 8(suppl 2):3-14
22. Soukharev S, Hammond D, Ananyeva NM, et al. Expression of factor VIII in recombinant and transgenic systems. Blood Cells Mol Dis 2002;28:234-248
23. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986;83:5939-5942
24. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993;81:2925-2935
25. Sandberg H, Almstedt A, Brandt J, et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001;85:93-100
26. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001;38:44-51
27. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001;38:52-59
28. Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost 2003;1:1349-1355
29. Kelley K, Venna I, Pierce GF. Gene therapy: reality or myth for the global bleeding disorders community? Haemophilia 2002;8:261-267
30. Plantier JL, Rodriguez MH, Enjolras N, Attali O, Negrier C. A factor VIII minigene comprising the truncated intron I of factor IX highly improves the in vitro production of factor VIII. Thromb Haemost 2001;86:596-603
31. Enjolras N, Rodriguez MH, Plantier JL, Maurice M, Attali O, Negrier C. The three in-frame ATG, clustered in the translation initiation sequence of human factor IX gene, are required for an optimal protein production. Thromb Haemost 1999;82:1264-1269
32. Kurachi S, Hitomi Y, Furukawa M, Kurachi K. Role of intron I in expression of the human factor IX gene. J Biol Chem 1995;270:5276-5281
33. Hoeben RC, Fallaux FJ, Cramer SJ, et al. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995;85:2447-2454
34. Dorner AJ, Wasley LC, Kaufman RJ. Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells. J Biol Chem 1989;264:20602-20607
35. Dorner AJ, Wasley LC, Kaufman RJ. Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J 1992;11:1563-1571
36. Dorner AJ, Wasley LC, Kaufman RJ. Protein dissociation from GRP78 and secretion are blocked by depletion of cellular ATP levels. Proc Natl Acad Sci USA 1990;87:7429-7432
37. Tagliavacca L, Wang Q, Kaufman RJ. ATP-dependent dissociation of non-disulfide-linked aggregates of coagulation factor VIII is a rate-limiting step for secretion. Biochemistry 2000;39:1973-1981
38. Marquette KA, Pittman DD, Kaufman RJ. A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem 1995;270:10297-10303
39. Swaroop M, Moussalli M, Pipe SW, Kaufman RJ. Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem 1997;272:24121-24124
40. Pittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor V expression and function. Blood 1994;84:4214-4225
41. Oeri J, Matter M, Isenschmid H, Hauser F, Koller F. Angeborener Mangel an Faktor V (Parahaemophilie) verbunden mit echter Haemophilie A bei zwei Brüdern. Med Probl Paediatr 1954;1:575
42. Nichols WC, Seligsohn U, Zivelin A, et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998;93:61-70
43. Nichols WC, Terry VH, Wheatley MA, et al. ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Blood 1999;93:2261-2266
44. Zhang B, Cunningham MA, Nichols WC, et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 2003;34:220-225
45. Herrmann JM, Malkus P, Schekman R. Out of the ER - outfitters, escorts and guides. Trends Cell Biol 1999;9:5-7
46. Kappeler F, Klopfenstein DR, Foguet M, Paccaud JP, Hauri HP. The recycling of ERGIC-53 in the early secretory pathway. ERGIC-53 carries a cytosolic endoplasmic reticulum-exit determinant interacting with COPII. J Biol Chem 1997;272:31801-31808
47. Scales SJ, Pepperkok R, Kreis TE. Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPII and COPI. Cell 1997;90:1137-1148
48. Campbell JL, Schekman R. Selective packaging of cargo molecules into endoplasmic reticulum-derived COPII vesicles. Proc Natl Acad Sci USA 1997;94:837-842
49. Vollenweider F, Kappeler F, Itin C, Hauri HP. Mistargeting of the lectin ERGIC-53 to the endoplasmic reticulum of HeLa cells impairs the secretion of a lysosomal enzyme. J Cell Biol 1998;142:377-389
50. Moussalli M, Pipe SW, Hauri HP, Nichols WC, Ginsburg D, Kaufman RJ. Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII. J Biol Chem 1999;274:32539-32542
51. Pipe SW, Miao HZ, Tendulkar R, Kaufman RJ. Asparagine-linked glycosylation sites within the B domain of coagulation factor VIII improve secretion efficiency. Blood 2001;98:705a (abst)
52. Pipe SW, Miao HZ, Sirachainan N, Cunningham MA, Kaufman RJ. Genetic modifications that increase factor VIII secretion in vitro and in vivo. J Thromb Haemost 2003; 1:OC091 (abst)
53. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002;277:38345-38349
54. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981;256:3433-3442
55. Voorberg J, van Stempvoort G, Bos JM, Mertens K, van Mourik JA, Donath MJ. Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid. J Biol Chem 1996;271:20985-20988
56. Hultin MB, Jesty J. The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin. Blood 1981;57:476-482
57. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990;265:1688-1692
58. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999;93:176-183
59. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001;97:685-691
60. Hakeos WH, Miao H, Sirachainan N, et al. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb Haemost 2002;88:781-787
61. Amano K, Michnick DA, Moussalli M, Kaufman RJ. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test. Thromb Haemost 1998;79:557-563
62. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997;94:11851-11856
63. Gale AJ, Pellequer JL, Griffin JH. A novel engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003;1:OC094 (abst)
64. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997;89:2413-2421
65. Gale AJ, Xu X, Pellequer JL, Getzoff ED, Griffin JH. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci 2002;11:2091-2101
66. Lenting PJ, Neels JG, van den Berg BM, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 1999;274:23734-23739
67. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999;274:37685-37692
68. Schwarz HP, Lenting PJ, Binder B, et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000;95:1703-1708
69. Neels JG, van den Berg BM, Mertens K, et al. Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 2000;96:3459-3465
70. Narita M, Rudolph AE, Miletich JP, Schwartz AL. The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo. Blood 1998;91:555-560
71. Kounnas MZ, Church FC, Argraves WS, Strickland DK. Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem 1996;271:6523-6529
72. Warshawsky I, Broze GJ Jr, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994;91:6664-6668
73. Turecek PL, Schwarz HP, Binder BR. In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor. Blood 2000;95:3637-3638
74. Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL. Catabolism of the coagulation factor VIII: can we prolong lifetime of fVIII in circulation? Trends Cardiovasc Med 2001;11:251-257
75. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001;276:11970-11979
76. Tuddenham EGD, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human hemophilia A and von Willebrand's disease. Br J Haematol 1982;52:259-267
77. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992;65:253-259
78. Over J, Sixma JJ, Bruine MH, et al. Survival of 125 iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978;62:223-234
79. Neels JG, Bovenschen N, van Zonneveld AJ, Lenting PJ. Interaction between factor VIII and LDL receptor-related protein. Modulation of coagulation? Trends Cardiovasc Med 2000;10:8-14
80. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002;99:1215-1223
81. Rodenburg KW, Kjoller L, Petersen HH, Andreasen PA. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Biochem J 1998;329:55-63
82. Howard GC, Yamaguchi Y, Misra UK, et al. Selective mutations in cloned and expressed alpha-macroglobulin receptor binding fragment alter binding to either the alpha2-macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor. J Biol Chem 1996;271:14105-14111
83. Knauer MF, Kridel SJ, Hawley SB, Knauer DJ. The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins. J Biol Chem 1997;272:29039-29045
84. Bovenschen N, Herz J, Grimbergen JM, et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003;101:3933-3939
85. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985;24:3736-3750
86. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant g-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986;261:9622-9628
87. Suttie JW. Synthesis of vitamin K-dependent proteins. FASEB J 1993;7:445-452
88. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982;79:6461-6464
89. Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998;35:11-17
90. Zheng B, Qiu XY, Tan M, et al. Increment of hFIX expression with endogenous intron 1 in vitro. Cell Res 1997;7:21-29
91. Rodriguez MH, Enjolras N, Plantier JL, et al. Expression of coagulation factor IX in a haematopoietic cell line. Thromb Haemost 2002;87:366-373
92. Schuettrumpf J, Herzog RW, Kaufhold A, Stafford DW, High KA, Arruda VR. Improving efficacy of gene therapy of hemophilia B by the use of mutant FIX variants. J Thromb Haemost 2003;1OC044 (abst)
93. Chang J, Jin J, Lollar P, et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998;273:12089-12094
94. Hopfner KP, Brandstetter H, Karcher A, et al. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. EMBO J 1997;16:6626-6635
95. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-155
96. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9
97. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997;77:825-828
98. Penick GD, Dejanov II, Roberts HR, Webster WP. Elevation of factor 8 in hypercoagulable states. Thromb Diath Haemorrh 1966;20(suppl):39-48
99. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994;88:601-607
100. Rosendaal FR, Varekamp I, Smit C, et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989;71:71-76
101. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-3682
102. Ton-That TT, Doron D, Pollard BS, Bacher J, Pollard HB. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat Biotechnol 2000;18:289-295
103. Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol 2001;38:48-50
104. Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates micropartides that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003;9:1020-1025